Intellia Therapeutics (NTLA) Stock Price Down 8.3%
Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) traded down 8.3% during mid-day trading on Friday . The company traded as low as $16.12 and last traded at $16.16. 556,954 shares changed hands during trading, a decline of 12% from the average session volume of 635,144 shares. The stock had previously closed at $17.62.
A number of analysts recently issued reports on the stock. BidaskClub upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 27th. Zacks Investment Research downgraded shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 29th. Chardan Capital restated a “buy” rating and set a $57.50 price objective on shares of Intellia Therapeutics in a report on Wednesday, February 27th. Leerink Swann assumed coverage on shares of Intellia Therapeutics in a report on Tuesday, November 27th. They set an “outperform” rating and a $23.00 price objective for the company. Finally, BTIG Research assumed coverage on shares of Intellia Therapeutics in a report on Thursday, February 7th. They set a “buy” rating and a $20.00 price objective for the company. Eight equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $29.08.
The company has a market capitalization of $730.84 million, a price-to-earnings ratio of -8.16 and a beta of 2.92.
In other Intellia Therapeutics news, EVP Andrew Schiermeier bought 7,500 shares of Intellia Therapeutics stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average price of $15.72 per share, for a total transaction of $117,900.00. Following the completion of the purchase, the executive vice president now directly owns 3,250 shares of the company’s stock, valued at $51,090. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.20% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of NTLA. Bank of New York Mellon Corp grew its stake in Intellia Therapeutics by 6.1% during the third quarter. Bank of New York Mellon Corp now owns 131,051 shares of the company’s stock valued at $3,751,000 after acquiring an additional 7,557 shares in the last quarter. BlackRock Inc. grew its stake in Intellia Therapeutics by 7.4% during the third quarter. BlackRock Inc. now owns 2,744,397 shares of the company’s stock valued at $78,545,000 after acquiring an additional 188,098 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in Intellia Therapeutics during the third quarter valued at approximately $1,236,000. Allianz Asset Management GmbH grew its stake in Intellia Therapeutics by 52.3% during the third quarter. Allianz Asset Management GmbH now owns 121,654 shares of the company’s stock valued at $3,482,000 after acquiring an additional 41,765 shares in the last quarter. Finally, Greenwoods Asset Management Ltd grew its stake in Intellia Therapeutics by 42.0% during the third quarter. Greenwoods Asset Management Ltd now owns 351,531 shares of the company’s stock valued at $10,061,000 after acquiring an additional 104,000 shares in the last quarter. 69.64% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Intellia Therapeutics (NTLA) Stock Price Down 8.3%” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2019/03/24/intellia-therapeutics-ntla-stock-price-down-8-3.html.
Intellia Therapeutics Company Profile (NASDAQ:NTLA)
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
See Also: What are the Benefits of Index Funds?
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.